Covered recipient · General Payments record
AHMED Z OBEIDAT
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$211,659.26
202 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $149,590.00 | 47 |
| Consulting Fee | $33,965.93 | 7 |
| Travel and Lodging | $22,209.77 | 66 |
| Food and Beverage | $5,893.56 | 82 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | $88,749.72 | 83 |
| Biogen, Inc. | $72,188.53 | 61 |
| Novartis Pharmaceuticals Corporation | $20,611.07 | 28 |
| GENZYME CORPORATION | $17,900.78 | 17 |
| Celgene Corporation | $7,513.24 | 8 |
| Genentech USA, Inc. | $4,581.33 | 4 |
| Medtronic USA, Inc. | $114.59 | 1 |
Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AHMED Z OBEIDAT
NPI 1184069627 · CMS profile ID 1382667
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
MILWAUKEE, WI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1184069627?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AHMED Z OBEIDAT, NPI 1184069627, CMS profile ID 1382667. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184069627?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). AHMED Z OBEIDAT, NPI 1184069627, CMS profile ID 1382667. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184069627?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- AHMED Z OBEIDAT, NPI 1184069627, CMS profile ID 1382667, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184069627?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
202 matching records · $211,659.26 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 202.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $3,045.00 | 10/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624519 | CMS |
| Novartis Pharmaceuticals Corporation | $2,350.00 | 10/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756403 | CMS |
| Novartis Pharmaceuticals Corporation | $125.00 | 10/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756407 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,045.00 | 10/15/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624511 | CMS |
| Alexion Pharmaceuticals, Inc. | $2,795.00 | 10/15/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624527 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,045.00 | 10/15/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624545 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,045.00 | 10/15/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624549 | CMS |
| Novartis Pharmaceuticals Corporation | $24.30 | 10/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756397 | CMS |
| Alexion Pharmaceuticals, Inc. | $121.81 | 10/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624433 | CMS |
| Alexion Pharmaceuticals, Inc. | $27.61 | 10/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624441 | CMS |
| Alexion Pharmaceuticals, Inc. | $159.85 | 10/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624445 | CMS |
| Novartis Pharmaceuticals Corporation | $2,350.00 | 10/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756391 | CMS |
| Novartis Pharmaceuticals Corporation | $105.00 | 10/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756395 | CMS |
| Alexion Pharmaceuticals, Inc. | $192.66 | 10/02/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624437 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,045.00 | 10/01/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624489 | CMS |
| GENZYME CORPORATION | $466.70 | 09/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694262829 | CMS |
| GENZYME CORPORATION | $7,785.00 | 09/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694263369 | CMS |
| GENZYME CORPORATION | $47.83 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694263371 | CMS |
| GENZYME CORPORATION | $69.99 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694263373 | CMS |
| GENZYME CORPORATION | $50.00 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694263375 | CMS |
| GENZYME CORPORATION | $218.61 | 09/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694263377 | CMS |
| GENZYME CORPORATION | $344.85 | 09/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694263887 | CMS |
| GENZYME CORPORATION | $39.13 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694329423 | CMS |
| Alexion Pharmaceuticals, Inc. | $2,795.00 | 09/26/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624515 | CMS |
| Biogen, Inc. | $3,675.00 | 09/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660596231 | CMS |
| Biogen, Inc. | $29.44 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660596233 | CMS |
| Celgene Corporation | $124.98 | 09/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672978747 | CMS |
| Biogen, Inc. | $150.00 | 09/20/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699344317 | CMS |
| Celgene Corporation | $6,820.00 | 09/18/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672863597 | CMS |
| Novartis Pharmaceuticals Corporation | $2,820.00 | 09/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756369 | CMS |
| Novartis Pharmaceuticals Corporation | $20.49 | 09/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756371 | CMS |
| Novartis Pharmaceuticals Corporation | $140.90 | 09/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756375 | CMS |
| Novartis Pharmaceuticals Corporation | $2,654.75 | 09/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756379 | CMS |
| Novartis Pharmaceuticals Corporation | $2,820.00 | 09/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756383 | CMS |
| Novartis Pharmaceuticals Corporation | $67.26 | 09/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756387 | CMS |
| Alexion Pharmaceuticals, Inc. | $82.57 | 08/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624385 | CMS |
| Alexion Pharmaceuticals, Inc. | $729.18 | 08/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624389 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,045.00 | 08/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624487 | CMS |
| Alexion Pharmaceuticals, Inc. | $84.66 | 08/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624377 | CMS |
| Alexion Pharmaceuticals, Inc. | $598.50 | 08/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624381 | CMS |
| Biogen, Inc. | $4,725.00 | 08/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660596311 | CMS |
| Biogen, Inc. | $47.88 | 08/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660596313 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,045.00 | 08/20/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624483 | CMS |
| Alexion Pharmaceuticals, Inc. | $39.84 | 08/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624370 | CMS |
| Alexion Pharmaceuticals, Inc. | $648.37 | 08/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624374 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,045.00 | 08/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695624495 | CMS |
| Novartis Pharmaceuticals Corporation | $14.73 | 08/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756355 | CMS |
| Novartis Pharmaceuticals Corporation | $2,350.00 | 08/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756359 | CMS |
| Novartis Pharmaceuticals Corporation | $123.50 | 08/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659756363 | CMS |
| Celgene Corporation | $384.66 | 08/02/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672963337 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,493.40 | 1 |
| PY2025 | Principal investigator | $1,436,185.73 | 133 |
| PY2024 | Recipient | $2,216.73 | 9 |
| PY2024 | Principal investigator | $1,016,038.70 | 64 |
| PY2023 | Recipient | $8,730.55 | 3 |
| PY2023 | Principal investigator | $755,692.27 | 62 |
| PY2022 | Principal investigator | $397,477.77 | 45 |
| PY2021 | Recipient | $5,540.28 | 3 |
| PY2021 | Principal investigator | $322,116.37 | 29 |
| PY2020 | Recipient | $960.00 | 2 |
| PY2020 | Principal investigator | $146,054.47 | 5 |
| PY2019 | Recipient | $851.48 | 11 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
134 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $19,411.70 | 12/22/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114124 |
| Principal investigator 1 | GENZYME CORPORATION | $153.75 | 12/22/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114128 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,299.56 | 12/22/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse | No dispute reported | 06/30/2026 | 1190303757 |
| Principal investigator 1 | Genentech, Inc. | $2,231.00 | 12/19/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666515 |
| Principal investigator 1 | Genentech, Inc. | $1,031.00 | 12/09/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666444 |
| Principal investigator 1 | Genentech, Inc. | $4,438.00 | 12/08/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666133 |
| Principal investigator 1 | Genentech, Inc. | $6,215.00 | 12/04/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666137 |
| Principal investigator 1 | TG Therapeutics, Inc. | $7,700.00 | 11/30/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226198081 |
| Principal investigator 1 | Genentech, Inc. | $1,587.00 | 11/18/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666128 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 11/18/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666509 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $74,775.50 | 11/17/2025 | Non-covered Recipient Entity Medical College Of Wisconsin, Incorporated | A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) | No dispute reported | 06/30/2026 | 1235995927 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $795.00 | 11/12/2025 | Non-covered Recipient Entity Medical College Of Wisconsin, Incorporated | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) | No dispute reported | 06/30/2026 | 1235995929 |
| Principal investigator 1 | Genentech, Inc. | $537.00 | 11/05/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666123 |
| Principal investigator 1 | Genentech, Inc. | $9,565.00 | 11/05/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666500 |
| Principal investigator 1 | GENZYME CORPORATION | $2,370.00 | 11/04/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114110 |
| Principal investigator 1 | GENZYME CORPORATION | $6,839.00 | 11/04/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114118 |
| Principal investigator 1 | Genentech, Inc. | $9,845.00 | 11/03/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211666399 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,512.50 | 11/01/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226198073 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,700.00 | 11/01/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226198079 |
| Principal investigator 1 | Genentech, Inc. | $46,188.00 | 10/28/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666440 |
| Principal investigator 1 | TG Therapeutics, Inc. | $438.82 | 10/28/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226198077 |
| Principal investigator 1 | GENZYME CORPORATION | $25,122.70 | 10/27/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114091 |
| Principal investigator 1 | GENZYME CORPORATION | $2,380.00 | 10/27/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114099 |
| Principal investigator 1 | GENZYME CORPORATION | $1,906.50 | 10/20/2025 | Non-covered Recipient Entity Interspond LLC | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148285 |
| Principal investigator 1 | GENZYME CORPORATION | $695.00 | 10/20/2025 | Non-covered Recipient Entity Interspond LLC | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148288 |
| Principal investigator 1 | GENZYME CORPORATION | $2,000.00 | 10/20/2025 | Non-covered Recipient Entity Interspond LLC | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148292 |
| Principal investigator 1 | GENZYME CORPORATION | $3,000.00 | 10/20/2025 | Non-covered Recipient Entity Interspond LLC | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148296 |
| Principal investigator 1 | GENZYME CORPORATION | $1,441.50 | 10/20/2025 | Non-covered Recipient Entity Interspond LLC | An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226148300 |
| Principal investigator 1 | Genentech, Inc. | $7,626.00 | 10/17/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666494 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,687.50 | 10/17/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226198075 |
| Principal investigator 1 | Genentech, Inc. | $2,636.00 | 10/15/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666117 |
| Principal investigator 1 | Genentech, Inc. | $1,566.00 | 10/15/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666502 |
| Principal investigator 1 | GENZYME CORPORATION | $1,159.00 | 10/14/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114105 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $34,992.47 | 10/14/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN | AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes | No dispute reported | 06/30/2026 | 1190300965 |
| Principal investigator 1 | Genentech, Inc. | $1,063.00 | 10/09/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666120 |
| Principal investigator 1 | Genentech, Inc. | $3,013.00 | 10/08/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666104 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $128.18 | 10/08/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN | A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension | No dispute reported | 06/30/2026 | 1190300639 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $903.52 | 10/07/2025 | Covered Recipient Teaching Hospital Childrens Hospital Of Wisconsin | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190298089 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,256.25 | 09/30/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226198021 |
| Principal investigator 1 | TG Therapeutics, Inc. | $600.00 | 09/30/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226198035 |
| Principal investigator 1 | Genentech, Inc. | $2,106.00 | 09/22/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666110 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,705.00 | 09/16/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226198025 |
| Principal investigator 1 | GENZYME CORPORATION | $26,174.40 | 09/08/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114085 |
| Principal investigator 1 | Genentech, Inc. | $9,484.00 | 09/08/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666107 |
| Principal investigator 1 | Genentech, Inc. | $2,613.00 | 09/03/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666490 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $423.00 | 09/01/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190306923 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $46,253.89 | 08/31/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190301057 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,906.25 | 08/31/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226198019 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,650.00 | 08/31/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226198033 |
| Principal investigator 1 | Genentech, Inc. | $9,416.00 | 08/26/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666431 |
| Principal investigator 1 | GENZYME CORPORATION | $3,606.00 | 08/25/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114080 |
| Principal investigator 1 | Genentech, Inc. | $8,390.00 | 08/20/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666435 |
| Principal investigator 1 | Genentech, Inc. | $631.00 | 08/08/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666113 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,437.25 | 07/31/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226198017 |
| Principal investigator 1 | TG Therapeutics, Inc. | $11,750.00 | 07/31/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226198031 |
| Principal investigator 1 | Genentech, Inc. | $1,150.00 | 07/29/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666098 |
| Principal investigator 1 | Genentech, Inc. | $9,565.00 | 07/29/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666485 |
| Principal investigator 1 | Genentech, Inc. | $6,418.75 | 07/25/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in MOG AD | No dispute reported | 06/30/2026 | 1211666388 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,625.00 | 07/24/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226198023 |
| Principal investigator 1 | Genentech, Inc. | $13,882.00 | 07/21/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666425 |
| Principal investigator 1 | Genentech, Inc. | $2,231.00 | 07/21/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666478 |
| Principal investigator 1 | EMD Serono, Inc. | $750.00 | 07/16/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118555 |
| Principal investigator 1 | GENZYME CORPORATION | $6,252.00 | 07/14/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114076 |
| Principal investigator 1 | Genentech, Inc. | $5,695.00 | 07/10/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666101 |
| Principal investigator 1 | Genentech, Inc. | $324.00 | 07/10/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666429 |
| Principal investigator 1 | Genentech, Inc. | $938.00 | 07/09/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666480 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,500.00 | 06/30/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197957 |
| Principal investigator 1 | Genentech, Inc. | $4,815.00 | 06/25/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666462 |
| Principal investigator 1 | EMD Serono, Inc. | $83.00 | 06/24/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118541 |
| Principal investigator 1 | EMD Serono, Inc. | $750.00 | 06/24/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118543 |
| Principal investigator 1 | EMD Serono, Inc. | $9,000.00 | 06/24/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118545 |
| Principal investigator 1 | EMD Serono, Inc. | $1,875.00 | 06/24/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118547 |
| Principal investigator 1 | EMD Serono, Inc. | $1,875.00 | 06/24/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118549 |
| Principal investigator 1 | EMD Serono, Inc. | $1,250.00 | 06/24/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118551 |
| Principal investigator 1 | EMD Serono, Inc. | $125.00 | 06/24/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118553 |
| Principal investigator 1 | Genentech, Inc. | $2,231.00 | 06/24/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666460 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,500.00 | 06/24/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190300465 |
| Principal investigator 1 | Genentech, Inc. | $1,956.00 | 06/20/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211666395 |
| Principal investigator 1 | Celgene Corporation | $15,623.00 | 06/16/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Emergency Medicine | A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) | No dispute reported | 06/30/2026 | 1222306519 |
| Principal investigator 1 | Genentech, Inc. | $937.50 | 06/04/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in MOG AD | No dispute reported | 06/30/2026 | 1211666372 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,615.00 | 06/01/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197955 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,835.00 | 05/29/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197953 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,412.38 | 05/27/2025 | Non-covered Recipient Entity Medical College Of Wisconsin | A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) | No dispute reported | 06/30/2026 | 1235995943 |
| Principal investigator 1 | GENZYME CORPORATION | $9,059.20 | 05/27/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114071 |
| Principal investigator 1 | Genentech, Inc. | $18,222.00 | 05/27/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666060 |
| Principal investigator 1 | Celgene Corporation | $2,550.00 | 05/21/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Emergency Medicine | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) | No dispute reported | 06/30/2026 | 1222306461 |
| Principal investigator 1 | Genentech, Inc. | $2,824.00 | 05/20/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666074 |
| Principal investigator 1 | Genentech, Inc. | $1,574.00 | 05/20/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666081 |
| Principal investigator 1 | Genentech, Inc. | $11,171.76 | 05/13/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666417 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,404.64 | 05/12/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197993 |
| Principal investigator 1 | Genentech, Inc. | $10,037.00 | 05/09/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in MOG AD | No dispute reported | 06/30/2026 | 1211666384 |
| Principal investigator 1 | Genentech, Inc. | $30,662.00 | 05/09/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666421 |
| Principal investigator 1 | GENZYME CORPORATION | $35,157.40 | 05/05/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114060 |
| Principal investigator 1 | Amgen Inc. | $53,863.50 | 05/02/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN INC | A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis | No dispute reported | 06/30/2026 | 1246644142 |
| Principal investigator 1 | TG Therapeutics, Inc. | $6,850.00 | 05/01/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197951 |
| Principal investigator 1 | Genentech, Inc. | $1,565.00 | 04/28/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666472 |
| Principal investigator 1 | Genentech, Inc. | $1,672.00 | 04/22/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666078 |
| Principal investigator 1 | Genentech, Inc. | $6,938.00 | 04/15/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666095 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $8,166.00 | 04/14/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN MEDICAL SCHOOL | A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) | No dispute reported | 06/30/2026 | 1185543472 |
| Principal investigator 1 | Genentech, Inc. | $937.50 | 04/14/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in MOG AD | No dispute reported | 06/30/2026 | 1211666380 |
| Principal investigator 1 | TG Therapeutics, Inc. | $106.25 | 04/14/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197947 |
| Principal investigator 1 | TG Therapeutics, Inc. | $17,570.00 | 04/14/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197949 |
| Principal investigator 1 | Celgene Corporation | $750.00 | 04/09/2025 | Non-covered Recipient Entity Clinical And Translational Science Institute | Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)- or No Disease Modifying Therapy | No dispute reported | 06/30/2026 | 1222307183 |
| Principal investigator 1 | Celgene Corporation | $4,833.33 | 04/09/2025 | Non-covered Recipient Entity Clinical And Translational Science Institute | A PHASE 3B, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOLOGICAL RESPONSE TO, AND THE SAFETY OF, THREE PARENTERALLY ADMINISTERED VACCINES IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO RECEIVE ORAL OZANIMOD, NON-PEGYLATED INTERFERON-, OR NO DISEASE MODIFYING THERAPY | No dispute reported | 06/30/2026 | 1222307199 |
| Recipient | F. Hoffmann-La Roche AG | $2,493.40 | 03/31/2025 | Covered Recipient Physician | Switch From Eculizumab to Satralizumab in Aquaporin 4 Immunoglobulin G–Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series Report | No dispute reported | 06/30/2026 | 1211534241 |
| Principal investigator 1 | Genentech, Inc. | $614.00 | 03/26/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666086 |
| Principal investigator 1 | Genentech, Inc. | $2,082.00 | 03/21/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666475 |
| Principal investigator 1 | Genentech, Inc. | $7,188.00 | 03/20/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666090 |
| Principal investigator 1 | Genentech, Inc. | $9,505.00 | 03/20/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666412 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,337.20 | 03/18/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197989 |
| Principal investigator 1 | Genentech, Inc. | $9,000.00 | 03/10/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211666393 |
| Principal investigator 1 | GENZYME CORPORATION | $3,723.00 | 03/04/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114033 |
| Principal investigator 1 | GENZYME CORPORATION | $7,503.00 | 03/04/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114041 |
| Principal investigator 1 | GENZYME CORPORATION | $10,534.70 | 03/04/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114047 |
| Principal investigator 1 | EMD Serono, Inc. | $125.00 | 03/03/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118535 |
| Principal investigator 1 | EMD Serono, Inc. | $1,250.00 | 03/03/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118537 |
| Principal investigator 1 | EMD Serono, Inc. | $325.00 | 03/03/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | No dispute reported | 06/30/2026 | 1240118539 |
| Principal investigator 1 | Genentech, Inc. | $6,539.00 | 02/20/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666063 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $240,136.73 | 02/19/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN INC | A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse | No dispute reported | 06/30/2026 | 1190307681 |
| Principal investigator 1 | Genentech, Inc. | $1,565.00 | 02/18/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666466 |
| Principal investigator 1 | Genentech, Inc. | $20,079.00 | 02/14/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666407 |
| Principal investigator 1 | Genentech, Inc. | $17,428.00 | 02/13/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | No dispute reported | 06/30/2026 | 1211666403 |
| Principal investigator 1 | Genentech, Inc. | $9,272.00 | 02/12/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in NMOSD patients 100kg | No dispute reported | 06/30/2026 | 1211666070 |
| Principal investigator 1 | TG Therapeutics, Inc. | $2,637.50 | 02/11/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197945 |
| Principal investigator 1 | Genentech, Inc. | $15,336.50 | 02/04/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Satralizumab in MOG AD | No dispute reported | 06/30/2026 | 1211666377 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $68,107.46 | 02/04/2025 | Non-covered Recipient Entity THE MEDICAL COLLEGE OF WISCONSIN | A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension | No dispute reported | 06/30/2026 | 1190300461 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,202.32 | 02/03/2025 | Non-covered Recipient Entity Froedtert & Medical College of Wisconsin 53226 | (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | No dispute reported | 06/30/2026 | 1226197987 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $1,440.50 | 01/22/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN EMERGENCY MEDICINE | A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) | No dispute reported | 06/30/2026 | 1185543470 |
| Principal investigator 1 | GENZYME CORPORATION | $36,740.00 | 01/21/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114054 |
| Principal investigator 1 | Genentech, Inc. | $2,231.00 | 01/17/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Evaluation of Fenebrutinib in RMS patients II | No dispute reported | 06/30/2026 | 1211666468 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $92,624.22 | 01/14/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN | AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes | No dispute reported | 06/30/2026 | 1190300967 |
| Principal investigator 1 | Genentech, Inc. | $625.00 | 01/08/2025 | Non-covered Recipient Entity The Medical College of Wisconsin, Inc. | Phase III study of Satralizumab in AE | No dispute reported | 06/30/2026 | 1211666066 |
| Principal investigator 1 | GENZYME CORPORATION | $36,740.00 | 01/06/2025 | Non-covered Recipient Entity Medical College Of Wisconsin Inc Att Department Of Medicine Administrati Co Wendy Wozney Medical Col | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis | No dispute reported | 06/30/2026 | 1226114065 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $39,062.15 | 01/01/2025 | Non-covered Recipient Entity MEDICAL COLLEGE OF WISCONSIN | A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension | No dispute reported | 06/30/2026 | 1190300641 |